AlphaThera

AlphaThera is a United States life-science tools company based in Philadelphia, Pennsylvania, that develops and sells reagents and services for antibody labeling and bioconjugation. Its core technology, marketed under the oYo-Link® brand, is a site-specific, covalent antibody labeling chemistry that the company says requires only about 30 seconds of hands-on time and roughly two hours of total conjugation time. The company positions oYo-Link as a simpler, more consistent alternative to conventional random labeling methods, emphasizing homogeneous conjugates with one to two labels per antibody, compatibility with common buffers, and high labeling efficiency. AlphaThera traces its origins to research in the laboratory of co-founder Dr. Andrew Tsourkas at the University of Pennsylvania. The company was co-founded in 2016 by Dr. Tsourkas and Dr. James Hui, and it has since grown into a commercial supplier with a portfolio of more than fifteen products. Its reagents are used in applications such as high-sensitivity ELISAs, flow cytometry, single-cell analysis, spatial omics, and antibody-drug conjugate research. The oYo-Link range includes biotin, oligo, DBCO, and drug-payload (such as VcMMAE and VcMMAF) labeling products, and the company's technology has been cited in peer-reviewed publications and preprints. Beyond reagents, AlphaThera offers antibody conjugation services in which its scientists perform site-specific labeling of customer antibodies with oligonucleotides, fluorophores, enzymes, biotin, or drug payloads, with optional purification. The company serves clients both domestically in the United States and worldwide, and it has received NIH grant support to advance its technology and commercial expansion.

AlphaThera was co-founded in 2016 by Dr. Andrew Tsourkas and Dr. James Hui. The company's scientific roots lie in the laboratory of Dr. Tsourkas at the University of Pennsylvania, where he is a Professor of Bioengineering and heads the Targeted Imaging, Therapeutics and Nanomedicine (TITAN) lab. Much of the early research in that lab focused on developing nanoparticles for imaging and treatment of diseases including cancer, atherosclerosis, and autoimmune diseases. According to the company's own account, efforts to scale up those particles or extend the work into new fields were severely limited, which motivated the development of a more practical bioconjugation approach. That approach became oYo-Link®, a site-specific antibody labeling technology that forms the core of AlphaThera's product portfolio. The company reports that it has launched more than fifteen different products and serves clients both in the United States and worldwide. It attributes its growth to translating novel laboratory discoveries into commercially valuable offerings for researchers. The oYo-Link method is designed to label off-the-shelf antibodies in under two hours with only about 30 seconds of hands-on time, giving researchers flexibility in designing experiments. AlphaThera has received NIH grant support, which it lists among the milestones of its development alongside its commercial expansion. Its reagents have been used in a range of applications, including high-sensitivity ELISAs, flow cytometry, single-cell analysis, and spatial omics, and its products have been cited in scientific literature such as Nature Communications, ACS journals, Antibody Therapeutics, and BioRxiv preprints. The company also offers antibody conjugation services, performing site-specific labeling of customer-supplied antibodies with oligonucleotides, fluorophores, enzymes, biotin, and drug payloads, with optional purification.

• 2016

  AlphaThera co-founded by Dr. Andrew Tsourkas and Dr. James Hui.

• Received NIH grant support for technology development.

• Launched more than 15 products and expanded commercially, serving domestic and worldwide clients.

Simple, fast, site-specific antibody labeling reagents and conjugation services for life-science researchers.

• oYo-Link® Biotin

  Site-specific biotinylation reagent for antibodies.

• oYo-Link® Oligo

  Site-specific oligonucleotide conjugation reagent for antibodies.

• oYo-Link® DBCO

  Site-specific DBCO labeling reagent for antibodies.

• oYo-Link® VcMMAE

  Antibody-drug conjugate reagent with VcMMAE payload.

• oYo-Link® VcMMAF

  Antibody-drug conjugate reagent with VcMMAF payload.

• Antibody conjugation service

  Site-specific antibody labeling service including oligonucleotide, fluorescent, enzyme, biotin, and drug conjugation, with optional purification.

1. 1Simple, fast, site-specific antibody labeling reagents | AlphaTheraalphathera.com
2. 2About us | AlphaTheraalphathera.com
3. 3Antibody Labeling & Conjugation Services - only $75 per conjugatealphathera.com
4. 4AlphaThera (United States) - Wikidatawikidata.org